TY  - GEN 
AU  - Markman, J. D.
AU  - Bolash, R. B.
AU  - McAlindon, T. E.
AU  - Kivitz, A. J.
AU  - POMBO SUAREZ, MANUEL ENRIQUE
AU  - Ohtori, S.
AU  - Roemer, F. W.
AU  - Li, D. J.
AU  - Viktrup, L.
AU  - Bramson, C.
AU  - West, C. R.
AU  - Verburg, K. M.
PY  - 2020
SN  - 0304-3959
UR  - http://hdl.handle.net/20.500.11940/16533
AB  - ABSTRACT: This randomized, double-blind, phase 3 study (56-week treatment; 24-week follow-up) assessed tanezumab in patients with chronic low back pain and history of inadequate response to standard-of-care analgesics (NCT02528253). Patients received...
KW  - Humans
KW  - Antibodies
KW  - Treatment Outcome
KW  - Pain Measurement
KW  - Double-Blind Method
TI  - Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
DO  - 10.1097/j.pain.0000000000001928
KW  - CHUS
VL  - 161
ER  -